June 21, 2010: Probiodrug AG, a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer’s disease, has been granted a US patent covering additional subject matters for the company’s QC inhibitors. The Patent comprises the use of QC inhibitors to treat mild cognitive impairment, neurodegeneration in Down Syndrome, Familial British and Familial Danish Dementia and the use of QC inhibitors to treat these diseases, as well as Alzheimer’s disease, in combination with additional agents.
Archived News
Facet Biotech and Trubion Pharmaceuticals form leukaemia collaboration
September 4, 2009: Facet Biotech Corporation and Trubion Pharmaceuticals, Inc have formed an agreement for the joint worldwide development and commercialisation of TRU-016, a product candidate in Phase I clinical development for chronic lymphocytic leukemia (CLL).
TRU-016 is a CD37-directed small modular immunopharmaceutical (SMIP™) protein therapeutic. The collaboration agreement includes TRU-016 in all indications and all other CD37-directed protein therapeutics.
